Tideglusib (NP-12, NP031112) is a selective and irreversible GSK3β inhibitor that was previously in clinical trials for Alzheimer’s disease and progressive supranuclear palsy [61,62,63]. Here, GSK3B is linked to early-onset autosomal dominant Alzheimer disease.